anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

130,621-130,680 of 319,975

filter-aware
293
The slide uses direct quotes and Q&A transcripts to undermine the credibility of the drug's launch prospects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
294
The slide uses direct quotes from a KOL to undermine the company's narrative of drug efficacy and market adoption.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
295
The slide uses a Q&A transcript format to highlight negative sentiment from a key opinion leader.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
296
The slide uses a Q&A transcript format to provide primary source evidence of a product flaw.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
297
The slide uses Q&A transcripts to undermine the competitive advantage of the Vykat tablet formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
298
The slide uses a Q&A format to highlight the investigator's lack of enthusiasm and low patient uptake.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
299
The slide uses direct Q&A transcripts to highlight the investigator's negative sentiment and concerns about patient safety (diabetes/hyperglycemia).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
300
The slide uses a Q&A format to highlight specific quotes from a trial investigator regarding drug safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
301
The slide uses a Q&A format to highlight specific allegations of misconduct regarding clinical trial reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
302
The slide uses a Q&A format to highlight potential misconduct by the company.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
303
The slide uses a Q&A format to highlight alleged unethical behavior by Soleno regarding academic integrity and investigator relations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
304
The slide uses a 'villain_critique' structure to undermine a competitor's clinical trial results by citing an expert's negative testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
305
The slide uses direct quotes from a trial investigator to undermine the drug's market potential and clinical efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
306
The slide uses a Q&A format to present qualitative evidence from a trial investigator.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
307
The slide uses a Q&A format to highlight the investigator's skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
308
The slide uses direct quotes from a trial investigator to undermine the validity of clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
309
The slide uses a Q&A format to frame the investigator's critique of the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
310
The slide uses bolding and highlighting to emphasize negative feedback from a key opinion leader.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
311
The slide uses a Q&A format to document expert testimony regarding trial integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
312
The slide uses a direct quote from an endocrinologist to cast doubt on the company's clinical data integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
313
The slide uses a Q&A format to highlight the expert's skepticism about the company's reporting practices.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
314
The slide uses a Q&A format to highlight expert opinion against the subject drug (DCCR/Vykat).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
315
Includes verbatim Q&A transcripts highlighting the investigator's passive approach to patient recruitment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
316
The slide uses Q&A transcripts to undermine the perceived market success of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
317
The slide uses direct quotes from a trial investigator to undermine the drug's clinical value and commercial prospects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
318
The slide uses a 'quote-as-evidence' structure to undermine the clinical efficacy of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
319
The slide uses a Q&A transcript format to expose flaws in clinical trial integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
320
The slide uses a Q&A format to present expert testimony from a trial investigator.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
321
The slide uses a Q&A transcript format to expose flaws in the clinical trial design regarding pill size.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
322
The slide uses a Q&A transcript format to undermine the company's product value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
323
The slide uses a combination of summary text and direct interview transcripts to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
324
The slide uses a Q&A format to highlight the failure of the trial's blinding protocol.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
325
The slide uses direct quotes from a pediatric endocrinologist to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
326
The slide uses Q&A transcripts to expose the risks of the drug and the burden of monitoring.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
327
The slide uses a bolded summary paragraph at the top, followed by a detailed Q&A transcript with yellow highlighting on key quotes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
328
The slide uses a Q&A transcript format to support the thesis that the competitor product is unnecessary or inferior.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
329
The slide uses a Q&A format to document expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
330
Includes direct Q&A transcripts from a trial investigator/endocrinologist.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
331
The slide uses direct quotes from an endocrinologist/KOL to undermine the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
332
The slide uses a direct quote from an endocrinologist to undermine the primary endpoint of a clinical trial.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
333
The slide uses direct quotes from a trial investigator to undermine the company's value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
334
The slide uses direct quotes from a trial investigator to undermine the value proposition of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
335
The slide uses direct quotes from an interview to highlight the discrepancy between public promotion and private clinical reality.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
336
The slide uses a Q&A format to highlight the investigator's reluctance and admission of clinical risks.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
337
Uses direct quotes from an investigator to undermine the credibility of clinical trial data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
338
The slide uses a Q&A transcript format to highlight potential misclassification of adverse events in a clinical trial.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
339
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
340
The slide presents a transcript of an expert consultation call to undermine the market potential of Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
341
The slide uses direct quotes from an expert consultation to undermine the product's value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
342
The slide uses a Q&A format to highlight the expert's negative sentiment toward the drug's efficacy and the company's investor materials.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
343
The slide presents a direct challenge to the commercial viability of 'Vykat' by highlighting a physician's preference for a cheaper, off-label alternative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
344
The slide uses a Q&A format to validate the expert's critique of the product's form factor.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
345
The slide uses expert quotes to undermine the company's claims regarding the drug's safety profile and market potential.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
346
The slide uses highlighted text to emphasize critical quotes from medical experts.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
347
The slide uses a combination of summary text and verbatim Q&A transcripts to highlight negative sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
348
The slide presents interview transcripts highlighting a lack of buzz at a major industry conference.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
349
The slide uses direct quotes to undermine the market potential and safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
350
The slide presents a Q&A format highlighting expert skepticism regarding the drug's safety profile and market relevance.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
351
The slide uses direct quotes to highlight physician skepticism and lack of awareness regarding the drug's trial flaws.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
352
The slide uses direct quotes to highlight the expert's negative sentiment toward the drug and the clinical trial methodology.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit